Researchers at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London have made a groundbreaking discovery that challenges the traditional understanding of the immune system's operation. Their study, published in the journal Brain, reveals crucial communication hubs
The pharmaceutical industry is currently experiencing a transformative period marked by evolving clinical trial dynamics, increased R&D investment, and significant post-pandemic adjustments. This transformation is primarily driven by the complexities of modern trials, the demands for personalized
Prostate cancer has become an alarming health issue, particularly among African men, who are increasingly found to be at higher risk compared to men of other ethnicities. Various studies point towards genetic factors playing a significant role in this elevated risk, coupled with inadequate
Scientists have long sought to understand the various factors that contribute to the prevalence of cancer, and recent research has shed light on a surprising potential culprit: Escherichia coli (E. coli). A study conducted by researchers from the Wellcome Sanger Institute and the University of
Cervical cancer, despite being largely preventable, continues to claim the lives of two women in the UK every day—a stark reminder of the ongoing battle against the disease. In a bid to change this grim statistic, NHS England has committed to an ambitious goal of eliminating cervical cancer by
The ability to control matter at the atomic level with remarkable precision has long been a dream in the field of nanotechnology. Recent advancements led by physicists at the University of Bath, in collaboration with an international team, have brought us closer to this goal. This breakthrough
In a groundbreaking development, QIMR Berghofer has made significant strides in combating severe viral infections in immunocompromised patients through their pioneering cell therapy. This innovative treatment has proven effective in 46 out of 71 patients, resulting in a notable 65% success rate.
Amgen's obesity drug candidate, MariTide (maridebart cafraglutide, formerly AMG 133), has brought forward promising results in a Phase II clinical trial, sparking hope for a new and effective treatment for obesity. With its innovative design and impressive efficacy, MariTide is positioned as a
Triple-negative breast cancer (TNBC) is a particularly aggressive form of breast cancer, accounting for 15-20% of all breast cancer cases. Known for its poor prognosis and lack of effective treatment options, TNBC presents a significant challenge in oncology. However, recent advancements in spatial
Heart disease remains a leading cause of mortality worldwide, with heart failure accounting for 13 percent of global deaths. The inability of the human heart to regenerate lost muscle cells after birth has driven the exploration of cell-based therapies. Over the past two decades, significant
